Xalkori (crizotinib) Capsules, for Oral Use
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
April 2016
ADVERSE REACTIONS
Clinical Trials Experience
Renal impairment
The estimated glomerular filtration...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts
More News: Clinical Trials | Drugs & Pharmacology